Literature DB >> 27094347

Treatment of Modifiable Risk Factors Is Associated With Decrease in Coronary Heart Disease Incidence: Time to Use the Polypill.

Steven G Chrysant1, George S Chrysant2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27094347      PMCID： PMC8031858          DOI： 10.1111/jch.12827

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  17 in total

1.  Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.

Authors:  Anil Patel; Tarang Shah; Gaurang Shah; Vijay Jha; Chinmoy Ghosh; Jagruti Desai; Bakulesh Khamar; Bhaswat S Chakraborty
Journal:  Am J Cardiovasc Drugs       Date:  2010       Impact factor: 3.571

2.  Heart disease and stroke statistics--2015 update: a report from the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Joshua Z Willey; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

Review 3.  Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Curr Hypertens Rep       Date:  2016-02       Impact factor: 5.369

4.  Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.

Authors:  Anthony J Viera; Stacey L Sheridan; Teresa Edwards; Elsayed Z Soliman; Russell Harris; Curt D Furberg
Journal:  Prev Med       Date:  2010-10-08       Impact factor: 4.018

5.  An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.

Authors:  Tracey-Lea Laba; Alison Hayes; Serigne Lo; David P Peiris; Tim Usherwood; Graham S Hillis; Natasha Rafter; Christopher M Reid; Andrew M Tonkin; Ruth Webster; Bruce C Neal; Alan Cass; Anushka Patel; Anthony Rodgers; Stephen Jan
Journal:  Med J Aust       Date:  2014-12-11       Impact factor: 7.738

6.  Could the polypill improve adherence? The patient perspective.

Authors:  Linda Bryant; Nataly Martini; Jacky Chan; Lisa Chang; Ahmed Marmoush; Belinda Robinson; Karen Yu; Many Wong
Journal:  J Prim Health Care       Date:  2013-03-01

7.  Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.

Authors:  Donald M Lloyd-Jones; Eric P Leip; Martin G Larson; Ralph B D'Agostino; Alexa Beiser; Peter W F Wilson; Philip A Wolf; Daniel Levy
Journal:  Circulation       Date:  2006-02-06       Impact factor: 29.690

8.  Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010.

Authors:  Earl S Ford
Journal:  J Am Coll Cardiol       Date:  2013-04-03       Impact factor: 24.094

9.  A polypill strategy to improve adherence: results from the FOCUS project.

Authors:  José M Castellano; Ginés Sanz; José L Peñalvo; Sameer Bansilal; Antonio Fernández-Ortiz; Luz Alvarez; Luis Guzmán; Juan Carlos Linares; Fernando García; Fabiana D'Aniello; Joan Albert Arnáiz; Sara Varea; Felipe Martínez; Alberto Lorenzatti; Iñaki Imaz; Luis M Sánchez-Gómez; Maria Carla Roncaglioni; Marta Baviera; Sidney C Smith; Kathryn Taubert; Stuart Pocock; Carlos Brotons; Michael E Farkouh; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2014-09-01       Impact factor: 24.094

10.  Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.

Authors:  Virginia Becerra; Alfredo Gracia; Kamal Desai; Seye Abogunrin; Sarah Brand; Ruth Chapman; Fernando García Alonso; Valentín Fuster; Ginés Sanz
Journal:  BMJ Open       Date:  2015-05-09       Impact factor: 2.692
View more
  2 in total

1.  Whole-Body Imaging Procedures in Resistant Hypertension: Evaluating for Secondary Causes or to Define End-Organ Damages?

Authors:  Mihály B Tapolyai; Ákos Pethő; Tibor Fülöp
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-10-19       Impact factor: 3.738

Review 2.  The polypill approach - An innovative strategy to improve cardiovascular health in Europe.

Authors:  Valentín Fuster; Francesc Gambús; Aldo Patriciello; Margaretha Hamrin; Diederick E Grobbee
Journal:  BMC Pharmacol Toxicol       Date:  2017-02-07       Impact factor: 2.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.